Use our HBOC Research Search tool to find and participate in research focused on hereditaty cancers. Need assistance getting started?
Here are some research studies that may be enrolling patients like you. Please check with the study contact and your health care provider to confirm your eligibility and see if the study is right for you. Note, our search tool may not be comprehensive and additional research resources can be found here.
The National Cancer Institute recently opened a clinical trial for prostate cancer screening in men who are at high risk for prostate cancer due to an inherited mutation. This is trial is for men without prostate cancer, ages 30 to 75, who have tested positive for Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, CHEK2, PALB2, RAD51D, BRIP1, FANCA. The trial involves screening MRI of the prostate every two years and biopsy of the prostate if the MRI is abnormal. There is no cost for travel or study-related tests.
The goal of the GENERATE study is to increase the uptake of genetic testing among family members of pancreatic cancer patients who may carry a genetic mutation.
This study involves education about genetic testing, undergoing genetic testing for cancer risk (for those who choose to) and completion of a series of 4 sets of questionnaires.
For more information, visit the study website.
A new study is recruiting people who received unexpected genetic test results about their cancer risk after having genetic testing done for some other reason.
This is a study of people with "secondary results” from genetic testing. Secondary results are unexpected. They are not related to the reason the person had the genetic test but are shared because they may be very important to the person’s health. Most secondary results have to do with high risks for health problems that can be treated or prevented. Many of these results are related to cancer risk. If you think you have received a secondary result, you may be eligible to join this study.
This study will validate and evaluate the performance of the IMMray PanCan-d test for pancreatic cancer diagnosis in comparison to standard of care imaging currently used in pancreatic cancer disease surveillance by the research sites’ institutions.
The Genetic Education for Men or GEM study, is a clinical trial evaluating educational tools for men from families in which a BRCA1/2 gene mutation has been identified. In order to identify untested men from BRCA1/2 families, we are seeking women who have received positive BRCA1/2 test results and have at least one untested male relative.
Women interested in the study should contact the project coordinator, Mary Kate Ladd, by phone at (877) 687-2720 (toll-free) or by email.
This is a study looking at esophageal ultrasound and Magnetic Resonance Imaging (MRI) as a screening for pancreatic cancer in high risk individuals.
The PHACT study offers genetic testing to women and men of Ashkenazi (Eastern European) Jewish ancestry, age 21 or older. This group is at least ten times more likely than the general population to inherit certain kinds of genetic mutations associated with cancer risk. The study is open to people who live in one of the nine Bay Area counties (Alameda, Contra Costa, Marin, Napa, San Francisco, San Mateo, Santa Clara, Solano, Sonoma). By participating in the UCSF Population Health and Cancer Testing (PHACT) study you will be provided with a saliva collection kit from Color Genomics, a genetic laboratory. Thirty genes will be analyzed, including BRCA1 and BRCA2, to identify mutations that increase the chance of cancer in both men and women of Ashkenazi (Eastern European) Jewish ancestry and genetic counseling support will be available with every test. For more information, visit the UCSF Center for BRCA Research.
The goal of the Wisdom Study is to determine if breast cancer screening can be made better by personalizing each woman’s mammogram schedule, compared to the current one-size-fits-all, annual approach. The Wisdom Study is designed to end the confusion about when to start and how often to have a mammogram. For more information, visit the WISDOM Study website.
|Clinical Trial||Official Title|
|NCT03979729||Breast Cancer Screening for Underserved Women: Comparing Outcomes and Lowering Recall Rates With 3D- vs. 2D-mammography|
|NCT03482557||Contrast Enhanced Spectral Mammography vs. MRI for Breast Cancer Screening|
|NCT03250078||A Pancreatic Cancer Screening Study in High Risk Individuals|
|NCT03937453||A Pancreatic Cancer Screening Study in Individuals With New-Onset Diabetes Mellitus|
|NCT03699995||MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma|
|NCT03726320||Trial of Community Health Worker-led Decision Coaching|
|NCT04175730||Prostate Cancer Detection Screening MRI Protocol|
|NCT04102722||Safety and Performance of the Multi-Modal UltraSound Tomography (MUST) Device in Breast Cancer Screening|
|NCT03474913||Upright MRI for Prostate Cancer Screening|
|NCT04030507||Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer|
|NCT03729115||A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer|
|NCT04397029||Assessing the Sensitivity of "SureTouch™" in Identifying Clinically Significant Masses in Women Undergoing Diagnostic and Screening Mammography|
|NCT03859492||Screening CEDM in Intermediate and High-Risk Patient Populations|
|NCT03726619||e-CHEC-uP: Scaling up an Efficacious Cancer Screening Intervention for Women With Limited English|
|NCT03408353||MERIT (Mammography, Early Detection Biomarkers, Risk Assessment, and Imaging Technologies) Cohort|
|NCT02511301||Circadian Thermal Sensing to Detect Breast Disease|
|NCT04085510||Tomosynthesis vs. Contrast-Enhanced Mammography in Women With Personal History of Breast Cancer in Western Pennsylvania|
|NCT03623945||Autoantibodies in Breast Cancer Detection|
|NCT03471650||Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer|
|NCT04124900||Telomere Associated Variables (TAVs) in Prostate Cancer|
|NCT01035112||Magnetic Resonance Imaging of Breast Cancer|
|NCT03568630||Blood Markers of Early Pancreas Cancer|
|NCT02033486||Digital Breast Tomosynthesis Guided Tomographic Optical Breast Imaging (TOBI)|
|NCT03984695||Sexual Health Empowerment for Women's Health|
|NCT03715959||Nipple Aspirate Fluid in Detecting Breast Cancer|
|NCT03953326||HeartPhone Cancer Survivors Trial 2019|
|NCT02206360||Pancreatic Cancer Early Detection Program|
|NCT03693378||A Study of IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups|
|NCT00539162||Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women|
|NCT00579514||Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients|
|NCT00579488||Clinical Significance of Germline BRCA Mutations|
|NCT03851133||Florida Pancreas Collaborative Next Generation Biobank|
|NCT04201223||Family Lifestyles, Actions, and Risk Education Intervention: Version 2|